Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease.

Invasive fungal disease (IFD) can be a severe treatment complication in patients with myeloid malignancies, but current risk models do not incorporate disease-specific factors, such as somatic gene mutations. Germline GATA2 deficiency is associated with a susceptibility to IFD. To determine whether myeloid gene mutations were associated with IFD risk, we identified 2 complementary cohorts of patients with myeloid malignancy, based on (1) the diagnosis of invasive aspergillosis (IA), or (2) the presence of GATA2 mutations identified during standard clinical sequencing. We found somatic GATA2 mutations in 5 of 27 consecutive patients who had myeloid malignancy and developed IA. Among 51 consecutive patients with GATA2 mutations identified in the evaluation of myeloid malignancy, we found that IFD was diagnosed and treated in 21 (41%), all of whom had received chemotherapy or had undergone an allogeneic stem cell transplant. Pulmonary infections and disseminated candidiasis were most common. The 90-day mortality was 52% among patients with IFD. Our results indicate that patients with somatic GATA2 mutations are a vulnerable subgroup of patients with myeloid malignancy who have high risk for treatment-associated IFD and suggest that a focused approach to antifungal prophylaxis be considered.

[1]  Shannon R. McCurdy,et al.  Risk of invasive fungal infections in patients with high‐risk MDS and AML receiving hypomethylating agents , 2020, American journal of hematology.

[2]  I. Solomon,et al.  Use of triazoles for the treatment of invasive aspergillosis: A three‐year cohort analysis , 2020, Mycoses.

[3]  J. Perfect,et al.  Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Orange,et al.  Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype , 2019, Leukemia & lymphoma.

[5]  T. Marafioti,et al.  Can somatic GATA2 mutation mimic germ line GATA2 mutation? , 2018, Blood advances.

[6]  S. Mccarroll,et al.  Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms , 2018, Science Translational Medicine.

[7]  T. Hohl Immune responses to invasive aspergillosis: new understanding and therapeutic opportunities , 2017, Current opinion in infectious diseases.

[8]  S. Gabriel,et al.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease , 2017, The New England journal of medicine.

[9]  D. Neuberg,et al.  Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.

[10]  J. Aster,et al.  Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. , 2016, The Journal of molecular diagnostics : JMD.

[11]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[12]  H. Greinix,et al.  Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study , 2015, BMC Infectious Diseases.

[13]  H. Blum,et al.  GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders , 2015, BMC Pulmonary Medicine.

[14]  D. Neuberg,et al.  Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. , 2015, Blood.

[15]  V. Bigley,et al.  Haematopoietic and immune defects associated with GATA2 mutation , 2015, British journal of haematology.

[16]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[17]  O. Dekkers,et al.  Relapsed and secondary disease drive the risk profile for invasive aspergillosis prior to stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome. , 2014, Medical mycology.

[18]  E. Estey,et al.  Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high‐grade myelodysplastic syndromes , 2014, American journal of hematology.

[19]  T. Hohl,et al.  Inflammatory Monocytes Orchestrate Innate Antifungal Immunity in the Lung , 2014, PLoS pathogens.

[20]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[21]  A. Kohlmann,et al.  GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis , 2013, Leukemia.

[22]  Sahar Mansour,et al.  Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome) , 2011, Nature Genetics.

[23]  Smita Y. Patel,et al.  Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. , 2011, Blood.

[24]  F. Marty,et al.  Invasive fungal disease in patients treated for newly diagnosed acute leukemia , 2010, American journal of hematology.

[25]  L. Cuzin,et al.  Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia , 2010, Haematologica.

[26]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[27]  M. Levenstein,et al.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.